glp 1 and medication absorption GLP-1 the kidney: from physiology to pharmacology and outcomes in diabetes Glucagon-like peptide-1 receptor: mechanisms and

Hello angels and welcome to the Glucose Goddess Show

In Phase 1 and 2a clinical trials, once-daily subcutaneous injections of RG7697 (0.252.5 mg) for 14 days in 56 patients with T2DM and 1.8 mg of RG7697 for 12 weeks in patients with T2DM who were poorly responsive to metformin reduced body weight and improved glycemic control

Oral Contraceptives Semaglutide's prescribing information includes a dedicated pharmacokinetic substudy evaluating co-administration with a combined oral contraceptive (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg)

Outcomes The primary outcomes were the glycemic markers FBG and HbA1c